Flavia Michelini
Overview
Explore the profile of Flavia Michelini including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
888
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gupta A, Michelini F, Shao H, Yeh C, Drago J, Liu D, et al.
Cell Rep Med
. 2024 Oct;
5(11):101792.
PMID: 39437778
Trastuzumab deruxtecan (T-DXd) is a human epidermal growth factor receptor 2 (HER2)-targeting antibody drug conjugate that has remarkable activity in HER2-positive cancers. However, the degree of benefit of T-DXd is...
2.
Li B, Meric-Bernstam F, Bardia A, Naito Y, Siena S, Aftimos P, et al.
Lancet Oncol
. 2024 May;
25(6):707-719.
PMID: 38710187
Background: Trastuzumab deruxtecan is a HER2-directed antibody-drug conjugate approved by the US Food and Drug Administration and the European Medicines Agency for HER2-mutant non-small-cell lung cancer. Few treatment options exist...
3.
Carro G, Guerbi X, Berra M, Rodriguez M, Noli M, Fuentes M, et al.
Foot Ankle Int
. 2024 Apr;
45(8):905-915.
PMID: 38676564
Background: Diabetic foot ulcers (DFUs) constitute a complication that occurs in 19% to 34% of patients with diabetes mellitus (DM). The aim of this study is to describe median days...
4.
King D, Smith A, Pineda G, Nakano M, Michelini F, Goedegebuure S, et al.
JCO Precis Oncol
. 2023 Apr;
7:e2100489.
PMID: 37079860
No abstract available.
5.
Ladewig E, Michelini F, Jhaveri K, Castel P, Carmona J, Fairchild L, et al.
Cancer Res
. 2022 Apr;
82(12):2269-2280.
PMID: 35442400
Significance: Transcriptomic analysis reveals a key role for the PI3K pathway in regulating RNA splicing, uncovering new mechanisms by which PI3K regulates proliferation and metabolism in breast cancer. See related...
6.
Giugliano F, Corti C, Tarantino P, Michelini F, Curigliano G
Curr Oncol Rep
. 2022 Mar;
24(7):809-817.
PMID: 35305211
Purpose Of Review: Summarizing the current preclinical and clinical evidence about bystander effect of antibody-drug conjugates (ADCs) in solid tumors. Recent Findings: One of the main challenges of treating solid...
7.
Cai Y, Xu G, Wu F, Michelini F, Chan C, Qu X, et al.
Cancer Res
. 2021 Mar;
81(9):2470-2480.
PMID: 33685991
PI3Kα inhibitors have shown clinical activity in PIK3CA-mutated estrogen receptor-positive (ER) patients with breast cancer. Using whole genome CRISPR/Cas9 sgRNA knockout screens, we identified and validated several negative regulators of...
8.
Sharma S, Anand R, Zhang X, Francia S, Michelini F, Galbiati A, et al.
Cell Rep
. 2021 Jan;
34(1):108565.
PMID: 33406426
The MRE11-RAD50-NBS1 (MRN) complex supports the synthesis of damage-induced long non-coding RNA (dilncRNA) by RNA polymerase II (RNAPII) from DNA double-strand breaks (DSBs) by an unknown mechanism. Here, we show...
9.
Li B, Michelini F, Misale S, Cocco E, Baldino L, Cai Y, et al.
Cancer Discov
. 2020 Mar;
10(5):674-687.
PMID: 32213539
Amplification of and oncogenic mutations in , the gene encoding the HER2 receptor tyrosine kinase, promote receptor hyperactivation and tumor growth. Here we demonstrate that HER2 ubiquitination and internalization, rather...
10.
Gioia U, Francia S, Cabrini M, Brambillasca S, Michelini F, Jones-Weinert C, et al.
Sci Rep
. 2019 Apr;
9(1):6460.
PMID: 31015566
A novel class of small non-coding RNAs called DNA damage response RNAs (DDRNAs) generated at DNA double-strand breaks (DSBs) in a DROSHA- and DICER-dependent manner has been shown to regulate...